ATE213409T1 - Zusammensetzungen zur behandlung und vorbeugung von krebs - Google Patents

Zusammensetzungen zur behandlung und vorbeugung von krebs

Info

Publication number
ATE213409T1
ATE213409T1 AT92922550T AT92922550T ATE213409T1 AT E213409 T1 ATE213409 T1 AT E213409T1 AT 92922550 T AT92922550 T AT 92922550T AT 92922550 T AT92922550 T AT 92922550T AT E213409 T1 ATE213409 T1 AT E213409T1
Authority
AT
Austria
Prior art keywords
compositions
treating
preventing cancer
pharmaceutically acceptable
stereoisomer
Prior art date
Application number
AT92922550T
Other languages
English (en)
Inventor
Dvorit Samid
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Priority claimed from PCT/US1992/008875 external-priority patent/WO1993007866A2/en
Application granted granted Critical
Publication of ATE213409T1 publication Critical patent/ATE213409T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92922550T 1991-10-21 1992-10-13 Zusammensetzungen zur behandlung und vorbeugung von krebs ATE213409T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/779,744 US6037376A (en) 1991-10-21 1991-10-21 Methods for therapy of cancer
PCT/US1992/008875 WO1993007866A2 (en) 1991-10-21 1992-10-13 Compositions and methods for therapy and prevention of cancer, aids, and anemia

Publications (1)

Publication Number Publication Date
ATE213409T1 true ATE213409T1 (de) 2002-03-15

Family

ID=25117401

Family Applications (3)

Application Number Title Priority Date Filing Date
AT92922550T ATE213409T1 (de) 1991-10-21 1992-10-13 Zusammensetzungen zur behandlung und vorbeugung von krebs
AT04015995T ATE406883T1 (de) 1991-10-21 1992-10-13 Antivirale mittel enthaltend phenylessigsäurederivate
AT04015994T ATE418975T1 (de) 1991-10-21 1992-10-13 Pharmazeutische zubereitungen zur behandlung von hemoglobulinopathien der beta-chain

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT04015995T ATE406883T1 (de) 1991-10-21 1992-10-13 Antivirale mittel enthaltend phenylessigsäurederivate
AT04015994T ATE418975T1 (de) 1991-10-21 1992-10-13 Pharmazeutische zubereitungen zur behandlung von hemoglobulinopathien der beta-chain

Country Status (9)

Country Link
US (2) US6037376A (de)
EP (4) EP1484059B1 (de)
AT (3) ATE213409T1 (de)
DE (3) DE69233743D1 (de)
DK (1) DK1484059T3 (de)
ES (2) ES2312884T3 (de)
HK (1) HK1067551A1 (de)
IL (1) IL103471A0 (de)
NZ (1) NZ244850A (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001285311B2 (en) 2000-08-29 2005-09-15 Biocon, Ltd Immunoregulatory compounds, derivatives thereof and their use
US7090839B2 (en) 2000-09-01 2006-08-15 Hidden Valley, N.V. Method of treatment of human immunodeficiency diseases
US6538030B2 (en) 2000-09-20 2003-03-25 Yih-Lin Chung Treating radiation fibrosis
US6372938B1 (en) 2001-05-21 2002-04-16 Stanislaw R. Burzynski Synthesis of 4-phenylbutyric acid
US8048924B2 (en) * 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
EP1291015A1 (de) * 2001-09-10 2003-03-12 Lunamed AG Darreichungsformen mit verlängerter Wirkstofffreisetzung
CN1642540A (zh) * 2002-03-26 2005-07-20 东弗吉尼亚医学院 作为局部杀微生物药和避孕药的苏拉明及其衍生物
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US8846039B2 (en) * 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US20060275370A1 (en) * 2002-07-25 2006-12-07 Yih-Lin Chung Method and compositions for treatment of epithelial damage
US8946295B2 (en) 2002-07-25 2015-02-03 Sunny Pharmtech Inc. Histone hyperacetylating agents for promoting wound healing and preventing scar formation
US8163764B2 (en) * 2002-04-26 2012-04-24 Asan Laboratories Company (Cayman) Limited Skincare methods
US6809118B2 (en) * 2002-07-25 2004-10-26 Yih-Lin Chung Methods for therapy of radiation cutaneous syndrome
US20040152784A1 (en) * 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
EP1574213B1 (de) * 2004-03-11 2008-07-09 Asan Laboratories Company (Cayman), Limited Verwendung von Histone Deacetylase Hemmern zur Steigerung der therapeutischen Wirkung in der Radiotherapie und Chemotherapie
ES2565848T3 (es) 2004-07-07 2016-04-07 Biocon Limited Síntesis de compuestos inmunorreguladores unidos por grupos azoicos
US20060045912A1 (en) * 2004-08-30 2006-03-02 Peter Truog 4-phenylbutyric acid controlled-release formulations for therapeutic use
US20060205818A1 (en) * 2005-03-08 2006-09-14 Burzynski Stanislaw R Method for the treatment of von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives
US20070004805A1 (en) * 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
EP1924245A2 (de) * 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Topische formulierungen von histondeacetylase-hemmern und verfahren zur verwendung derselben
US20090054498A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Anhydrous Compositions Useful for Attaining Enhanced Sexual Wellness
US20090054497A1 (en) * 2007-08-21 2009-02-26 Nawaz Ahmad Methods for attaining enhanced sexual wellness using anhydrous compositions
US20110301153A1 (en) * 2008-11-17 2011-12-08 The Trustees Of The University Of Pennsylvania Methods of treating cancer
AU2018269937A1 (en) * 2017-05-19 2020-01-02 Memorial Sloan Kettering Cancer Center Methods for modifying endoplasmic reticulum processing of protein
WO2021149127A1 (ja) * 2020-01-21 2021-07-29 オリンパス株式会社 赤血球分化モニタリング装置および赤血球分化モニタリング方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4028404A (en) * 1967-07-31 1977-06-07 Allen & Hanburys Limited Acetic acid derivatives
US3998966A (en) * 1971-11-04 1976-12-21 Syntex Corporation Anti-inflammatory, analgesic, anti-pyretic and anti-pruritic 6-substituted 2-naphthyl acetic acid derivative-containing compositions and methods of use thereof
CH576447A5 (de) * 1972-03-10 1976-06-15 Ciba Geigy Ag
CS181686B2 (en) * 1974-01-14 1978-03-31 Isf Spa Process for preparing 4-cyclopropylmethylenoxy-3-chlorphenylacetic acid
GB1511645A (en) * 1974-05-31 1978-05-24 Univ Ife Sickle cell anaemia treatment
US4137309A (en) * 1976-10-14 1979-01-30 The Procter & Gamble Company Therapeutic treatment
US4282214A (en) * 1978-07-31 1981-08-04 The Procter & Gamble Company Phenylacetate anti-inflammatory composition
JPS57193437A (en) * 1981-05-21 1982-11-27 Ajinomoto Co Inc Amino acid derivative
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
JPS58194814A (ja) * 1982-05-11 1983-11-12 Nippon Shinyaku Co Ltd 免疫調節作用を有する薬剤
US4457942A (en) * 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
IT1170238B (it) * 1982-12-06 1987-06-03 Upjohn Co Impiego di ibuprofene e flurbiprofene nella cura dell'erpete
US4851404A (en) * 1983-07-05 1989-07-25 Miles Inc. Method of treating hemoglobinopathy
US4822821A (en) * 1986-10-10 1989-04-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
US5025029A (en) * 1986-10-10 1991-06-18 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin
JPH02207021A (ja) * 1989-02-07 1990-08-16 Ono Pharmaceut Co Ltd グアニジノ安息香酸誘導体を有効成分として含有する抗レトロウイルス剤
US5254587A (en) * 1990-09-04 1993-10-19 Burzynski Stanislaw R Methods for treating AIDS

Also Published As

Publication number Publication date
EP1108428A3 (de) 2004-01-07
HK1067551A1 (en) 2005-04-15
ATE418975T1 (de) 2009-01-15
EP1108428A9 (de) 2001-10-31
ES2312884T3 (es) 2009-03-01
DE69232426D1 (de) 2002-03-28
EP1484058A3 (de) 2005-04-27
EP1484059B1 (de) 2008-09-03
EP1484058A2 (de) 2004-12-08
US5877213A (en) 1999-03-02
EP1108427A2 (de) 2001-06-20
DE69232426T2 (de) 2002-10-10
EP1484058B1 (de) 2008-12-31
NZ244850A (en) 1997-01-29
EP1484059A2 (de) 2004-12-08
DE69233743D1 (de) 2008-10-16
EP1108427A3 (de) 2004-01-07
ES2171400T3 (es) 2002-09-16
ATE406883T1 (de) 2008-09-15
EP1108428A2 (de) 2001-06-20
DK1484059T3 (da) 2008-12-01
US6037376A (en) 2000-03-14
DE69233754D1 (de) 2009-02-12
EP1484059A3 (de) 2005-04-20
IL103471A0 (en) 1993-03-15

Similar Documents

Publication Publication Date Title
ATE213409T1 (de) Zusammensetzungen zur behandlung und vorbeugung von krebs
IL97049A0 (en) Aryl-and heteroarylethenylene derivatives,their preparation and pharmaceutical compositions containing them
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
ATE209034T1 (de) Taxolderivate
ES2109276T3 (es) Derivados de tropolona y composicion farmaceutica de los mismos para prevenir y tratar enfermedades isquemicas.
DE3363105D1 (en) (omega-(diethylamino)-alkoxy)-alpha-(ethyl)-benzhydrol derivatives, their acid addition salts and quaternary salts, process for their preparation and medicines containing these compounds
ATE110721T1 (de) 2-alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische zusammensetzungen.
CA2317673A1 (en) Novel allylthiopyridazine derivatives and process for preparing the same
FI834800A (fi) Foerfarande foer framstaellning av dialkylaminoalkoxibensylalkohol-derivat.
ES8300096A1 (es) "un procedimiento para preparar derivados de halofenil-piridil-alilamina".
GB2021559A (en) Benzylidene derivatives
ATE100463T1 (de) Renin-hemmende aminooligohydroxy-derivate.
FI834797A0 (fi) Foerfarande foer framstaellning av resorcinderivat
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
ATE109485T1 (de) Derivate von n-(vincristinyl-23) und n- (noranhydro-5-vinblastinyl-23) von amino-1- methylphosphonsäure, ihre verfahren zur herstellung und sie enthaltende pharmazeutische zusammensetzungen.
JPS56131551A (en) Tyrosine derivative and medicinal use
DK601883A (da) Phenyl-propanolderivater

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties